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long-term functional improvements in the 2-year 
treatment of schizophrenia outpatients with 
olanzapine long-acting injection
Background: Little is known about the long-term changes in the functioning of schizophrenia 
patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether 
observed changes differ from those seen with oral olanzapine.
Methods: This study describes changes in the levels of functioning among outpatients with 
schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This 
was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study 
comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; 
n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with 
the Heinrichs–Carpenter Quality of Life Scale. Functional status was also classified as “good”, 
“moderate”, or “poor”, using a previous data-driven approach. Changes in functional levels were 
assessed with McNemar’s test and comparisons between olanzapine-LAI and oral olanzapine 
employed the Student’s t-test. 
Results: Over the 2-year study, the patients treated with olanzapine-LAI improved their level 
of functioning (per Quality of Life total score) from 64.0–70.8 (P0.001). Patients on oral 
 olanzapine also increased their level of functioning from 62.1–70.1 (P0.001). At baseline, 
19.2% of the olanzapine-LAI-treated patients had a “good” level of functioning, which increased 
to 27.5% (P0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively 
(P0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. 
Conclusion: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with 
schizophrenia maintained or improved their favorable baseline level of functioning over time. 
Results did not significantly differ between olanzapine-LAI and oral olanzapine. 
Keywords: antipsychotics, functioning, olanzapine long-acting injection, quality of life, 
schizophrenia
Introduction
Schizophrenia is often a chronic and severe illness characterized by impairment in 
thinking, feeling, and behavior; it is accompanied by impaired functioning, low levels of 
productivity, and high rates of unemployment.1,2 According to the consensus guidelines 
for the treatment of patients with schizophrenia, antipsychotics are the cornerstone in 
the treatment of the illness; maximizing patient quality of life and adaptive functioning 
are the primary treatment goals.3–7
Prior antipsychotic research has shown that olanzapine in an oral tablet formulation 
is associated with favorable functional improvements in the acute and maintenance 
treatment of patients with schizophrenia.8–11 Olanzapine is also available in long-acting 
injection formulation (LAI, depot), which was shown to significantly improve patient 





level of functioning compared with placebo in an 8-week, 
acute-phase study of schizophrenia.12 Practice guidelines for 
schizophrenia management recommend depot antipsychotics 
for patients who are nonadherent with their medication.4 Up 
to one-third of outpatients are reported to be nonadherent, and 
another third are reported to be only partially adherent.13 Fur-
thermore, patient adherence has been found to deteriorate 
over time, with up to three-fourths of patients demonstrating 
only partial adherence after 2 years of treatment.14 Medica-
tion adherence has been previously shown to predict relapse 
and hospitalization,15 which tend to signal patients’ growing 
difficulties to function in the community.16
Although there is evidence supporting the effectiveness 
of olanzapine-LAI17,18 and the associated short-term improve-
ments in patient functioning and quality of life,12 little is 
known about long-term changes in the level of functioning 
in schizophrenia patients receiving maintenance therapy with 
olanzapine-LAI, and whether observed changes differ from 
those seen with oral olanzapine.
The primary objective of the present analysis was to 
describe the changes in the level of functioning among 
schizophrenia patients receiving long-term maintenance 
therapy with olanzapine-LAI, using data from a 2-year, 
randomized, open-label maintenance study of outpatients 
with schizophrenia that compared monthly olanzapine-LAI 
therapy with daily oral olanzapine therapy. As a secondary 
objective of this analysis, observed functional changes were 
compared between patients treated with olanzapine-LAI or 
oral olanzapine.
Materials and methods
study design and participants
This was a secondary analysis of data from a multicenter, 
randomized, open-label, 2-year study comparing the long-
term treatment effectiveness and safety of olanzapine-LAI 
with that of daily oral olanzapine in schizophrenia outpatients 
(ClinicalTrials.gov registration number: NCT00320489; 
code: F1D-MC-HGLQ).19 
Participants were aged 18–65 years, with a Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition 
or Fourth Edition-Text Revision diagnosis of schizophrenia, 
with a Positive and Negative Syndrome Scale (PANSS) 
total score 70 and a Clinical Global Impression–Severity 
(CGI-S) scale rating of 4, who had not been hospitalized 
in the 8 weeks before study inclusion, and who were at 
risk for relapse as demonstrated by at least two episodes of 
clinical worsening in the past 24 months (2 years) (ie, the 
patient was hospitalized or required an increased level of 
care surrounding the episode). Exclusion criteria included: 
significant suicidal or homicidal risk; pregnancy or breast-
feeding; acute, serious, or unstable medical conditions; or 
substance dependence (except nicotine or caffeine) within 
the past month. 
The study design consisted of two periods – a screen-
ing phase during which the patients were screened for 
eligibility (in visit one and in visit two) and an open-label 
treatment phase lasting up to 104 weeks. Patients were 
randomly assigned in a 1:1 ratio to receive olanzapine-LAI 
(405 mg/4 weeks, n=264) or oral olanzapine (10 mg/day, 
n=260). Dosing was flexible following the initial random-
ization dose (150–405 mg/4 weeks for olanzapine-LAI, and 
5–20 mg/day for oral olanzapine).
No oral antipsychotic supplementation was allowed after 
week 8. Concomitant medications with primarily central 
nervous system activity were prohibited, except for benzo-
diazepines and sedative-hypnotics as sleep aids (2 mg/day 
lorazepam equivalents) and any antidepressants that the 
patient was already taking (except for fluvoxamine, which 
was prohibited). 
The study protocol was approved by institutional review 
boards at each site. After receiving a complete descrip-
tion of the study, all patients and/or their authorized legal 
representatives provided written informed consent before 
participation. 
Measures
Level of functioning was measured with the Heinrichs–
Carpenter Quality of Life Scale (QLS).20 The QLS is a 
clinician-rated scale used to assess the impact of schizophre-
nia on occupational, social, and psychological functioning in 
patients with schizophrenia. The scale consists of 21 items 
rated on a 7-point scale from normal or unimpaired func-
tioning (scores of 5 or 6) to impaired functioning (scores 
of 0 and 1). The QLS items assess four domains: intrapsy-
chic foundation; interpersonal relations; instrumental role; 
and common objects and activities. The QLS scale was 
administered at baseline, at 22 weeks, at 46 weeks, and at 
70 weeks thereafter and at endpoint (104 weeks or at the 
discontinuation visit). Patient functioning was also classified 
using cut-off points developed using the QLS.21 Patients were 
considered to have: a “good” level of functioning if the QLS 
total score was 84.5; a “moderate” level if the QLS total 
score was 84.5, and the QLS Intrapsychic foundation score 
was 15.5; and a “poor” level of functioning if the QLS total 
score was 84.5 and the QLS intrapsychic foundation score 
was 15.5. In addition to levels of functioning, symptom 
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severity was assessed using the 30-item PANSS22 and the 
CGI-S scale.23 
statistical methods
The patients included in the analyses were those randomized 
patients with at least one postbaseline assessment; the last 
observation carried forward methodology was employed. 
A total of 524 patients were included; 264 (50.4%) received 
olanzapine-LAI, and 260 (49.6%) received oral olanzapine. 
Changes in the level of functioning from baseline during the 
study were assessed with McNemar’s test, and comparisons 
between olanzapine-LAI and oral olanzapine on level of 
functioning per QLS total score employed the Student’s t-test. 
All analyses were performed using SAS, version 9.1 (SAS 
Institute Inc., Cary, NC, USA).
Results
The baseline sociodemographic and clinical characteristics 
of the patients in the two treatment groups are shown in 
Table 1. There were no significant differences between the 
 olanzapine-LAI and the oral olanzapine groups. About one-third 
of the patients in both groups were women. Mean age at study 
entry was about 41 years, and the mean time since the onset 
of schizophrenia was about 26 years. Baseline illness severity 
was within the mild range and similar across the two groups; 
the mean CGI-S score was 3.2 for olanzapine-LAI and 3.3 for 
oral olanzapine, indicating that these patients were mildly ill. 
Similarly, the total PANSS scores were about 57 for both 
groups, a score consistent with being mildly ill with regard 
to symptomatology.24 Roughly 20% of the patients were 
unemployed, and about one-fourth were living independently. 
There were no group differences in the proportion of patients 
who discontinued before the end of the study.
Over the 2-year study, patients treated with olanzapine-
LAI improved their level of functioning (QLS total score) 
from a mean of 64.0–70.8 (P0.001) (Table 2). Patients 
taking oral olanzapine increased their QLS total score from 
62.1–70.1 (P0.001).
At baseline, 19.2% of the olanzapine LAI-treated patients 
were identified as having a “good” level of functioning, 
Table 1 Baseline sociodemographic and clinical characteristics, by treatment
Characteristic Olanzapine-LAI Olanzapine Pa
Number of patients (n=264) (n=260)
Female, n (%) 89 (33.7) 83 (31.9) 0.66
age at study entry (years), mean (sD) 41.7 (10.9) 40.1 (10.8) 0.09
age at onset (years), mean (sD) 25.9 (9.2) 26.5 (8.7) 0.28
cgi-s score, mean (sD) 3.2 (0.8) 3.3 (0.7) 0.82
PaNss total score, mean (sD) 56.7 (9.8) 56.6 (8.7) 0.43
in paid employment, n (%) 56 (21.3) 48 (18.5) 0.43
living independently, n (%) 67 (25.5) 56 (21.6) 0.29
Note: aP-value comparing olanzapine-lai with oral olanzapine.
Abbreviations: lai, long-acting injection; sD, standard deviation; cgi-s, clinical global impression–severity; PaNss, Positive and Negative symptom scale.
Table 2 change in level of functioning per Qls total and Qls subscale scores from baseline to last observation, by treatment group
QLS score/visit Olanzapine-LAIa Pb Oral olanzapine Pb
QLS total score, mean (SD)
Baseline 64.0 (21.2) 0.001 62.1 (18.8) 0.001
last observation years 70.8 (22.9) 70.1 (22.4)
QLS common objects and activities, mean (SD)
Baseline 6.6 (2.6) 0.001 6.5 (2.5) 0.001
last observation 7.3 (2.6) 7.1 (2.6)
QLS intrapsychic foundation, mean (SD)
Baseline 21.9 (7.9) 0.001 21.6 (6.9) 0.001
last observation 24.1 (8.7) 23.9 (8.4)
QLS intrapersonal relation, mean (SD)
Baseline 21.0 (10.0) 0.001 20.0 (9.3) 0.001
last observation 24.2 (10.2) 23.9 (10.0)
QLS instrumental role, mean (SD)
Baseline 14.1 (3.6) 0.001 13.9 (3.2) 0.001
2 years 14.8 (3.9) 14.8 (3.8)
Notes: aThere were no statistical differences between olanzapine-lai and oral olanzapine in any of the ratings. bP value; change from baseline to endpoint.
Abbreviations: lai, long-acting injection; sD, standard deviation; Qls, Quality of life scale.





which increased to 27.5% following up to 2 years of therapy 
(Table 3). There was a numerical, but not a statistically 
significant, decrease in the proportion of patients with a 
“moderate” level of functioning (from 57.5%–52.1%) and in 
the proportion of patients with a “poor” level of functioning 
(from 23.4%–20.4%). Results were not significantly dif-
ferent between the oral olanzapine and the olanzapine-LAI 
treatment groups.
Baseline characteristics of the patients in the “good”, 
“moderate”, and “poor” functional clusters are shown in 
Table 4. There were significant differences between the 
groups for CGI-S score, PANSS total score, and functioning 
parameters, but not between the groups in the proportion of 
females, age at study entry, and time since illness onset.
The proportion of patients in the “good”, “moderate”, 
and “poor” functioning clusters at endpoint, by their baseline 
functional cluster and treatment group, are shown in Table 5. 
Although there was some variability within each group, there 
was a consistent trend toward an increase in the proportion 
of patients in the “good” functioning cluster.
Discussion
In this 2-year, randomized, open-label maintenance study, 
schizophrenia patients who were treated with  olanzapine-LAI 
experienced a significant improvement in their level of 
functioning over time. The improvements were observed 
in the total QLS score and in each of its four functional 
domains: interpersonal; instrumental (occupational); intra-
psychic (motivational); and in common objects and activities 
(a domain that may reflect a patient’s ability to function in the 
community). Moreover, when using the functional categories 
of “good”, “moderate”, and “poor” to assess change in func-
tional levels, most patients (73.5%–76.1%) maintained their 
“good” baseline level of functioning, and some moved from 
“moderate” and “poor” to the “good” functional category. 
More specifically, of the patients treated with olanzapine-
LAI, 18.8% moved from “moderate” to “good” levels of 
functioning and 9.1% moved from “poor” to “good”. Of 
patients treated with oral olanzapine, a similar proportion 
of patients moved from “moderate” to “good” levels of 
functioning (19.6%) but a numerically smaller proportion 
(2.4%) moved from “poor” to “good”. Overall, the observed 
improvements in QLS scores and in the proportion of patients 
in the “good” functional category did not differ significantly 
between patients treated with monthly olanzapine-LAI and 
daily oral olanzapine. 
The current assessment of levels of functioning in the 
long-term maintenance study of patients with  schizophrenia 
Table 3 Proportion of patients with “good”, “moderate”, and “poor” levels of functioning at baseline and last observation, 
by treatment group
Visit/functioning cluster Olanzapine-LAI Oral olanzapine Total Pa
Baseline, n (%) 0.11
“good” 50 (19.2) 37 (14.2) 87
“Moderate” 150 (57.5) 172 (66.2) 322
“Poor” 61 (23.4) 51 (19.6) 112
2 years, n (%) 0.26
“good” 66 (27.5) 56 (24.5) 122
“Moderate” 125 (52.1) 136 (59.4) 261
“Poor” 49 (20.4) 37 (16.2) 86
Note: aP value comparing the proportion of patients in each cluster between olanzapine-lai and oral olanzapine.
Abbreviation: lai, long-acting injection.
Table 4 Baseline characteristics of the patients in the “good”, “moderate”, and “poor” functional clusters (all patients, n=524)
Characteristic Functioning cluster Pa
“Good” “Moderate” “Poor”
Number of patients (n=87) (n=322) (n=112)
Female, n (%) 33 (38) 102 (32) 36 (32) 0.5367
age at study entry (years), mean (sD) 39.2 (11.4) 40.8 (10.7) 42.7 (10.9) 0.0928
Time since onset (years), mean (sD) 13.9 (11.2) 14.6 (10.2) 15.8 (10.7) 0.2367
cgi-s score, mean (sD) 2.7 (0.9) 3.3 (0.7) 3.5 (0.6) 0.0001
PaNss total score, mean (sD) 50.0 (10.5) 57.1 (8.4) 60.3 (7.9) 0.0001
in paid employment, n (%) 39 (45) 59 (18) 6 (5) 0.0001
living independently, n (%) 25 (29) 84 (26) 13 (12) 0.0032
Note: aP value comparing the three clusters.
Abbreviations: sD, standard deviation; cgi-s, clinical global impression-severity; PaNss, Positive and Negative symptom scale.
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provides valuable information for patients, clinicians, and 
other health care decision makers about the value of antip-
sychotic therapy, and – specifically – about olanzapine 
therapy in depot or oral formulations, to enhance the patients’ 
functional status, and thus their potential ability to achieve 
greater reintegration into society. While antipsychotic 
medications play an important role in achieving this goal, 
it appears that a patient’s level of functioning depends on a 
host of factors, including his or her symptom severity level, 
various social and environmental factors,25,26 and the level 
of cognitive deficits.27 
Our findings are consistent with a previous study  showing 
that patients receiving another long-acting atypical anti-
psychotic (risperidone-LAI) also experience improvements 
in functioning over the course of maintenance treatment, 
although our findings apply to a longer period of time28,29 and 
provide a relevant comparison group (the oral counterpart of 
the depot formulation) that is typically missing from prior 
research efforts.
limitations
Current findings need to be evaluated in the context of the 
study limitations. First, the present study included a patient 
population that was clinically stable on oral olanzapine at 
baseline, manifested a relative low level of symptom sever-
ity, and had a substantial proportion of patients whose level 
of functioning was deemed to be “good”. These relatively 
favorable baseline patient characteristics may have created a 
ceiling effect that curtailed the ability to find marked improve-
ments from baseline and may have also reduced the ability 
to differentiate between the two treatment groups. Second, 
as with other randomized clinical trials of  schizophrenia 
patients,30 this randomized trial included mostly adherent 
patients. In such an adherent patient population, it is difficult 
to differentiate between oral and depot therapy, although 
differences between these formulations are likely to mani-
fest in real world practice where long-acting injections are 
often reserved for nonadherent patients. Third, in this 
study, the highest possible dose of olanzapine-LAI was 
405 mg/4 weeks, which is comparable to 15 mg/day of oral 
olanzapine. However, patients randomized to oral olanzapine 
could receive a higher dose – up to 20 mg/day. Therefore, it 
is possible that patients treated with oral olanzapine (but not 
patients treated with olanzapine-LAI) could be rescued with a 
higher dose of the medication, if needed. Thus, although the 
two treatment groups did not differ significantly on functional 
outcomes, the difference in the maximum daily dose may 
have placed the olanzapine-LAI treatment group at a relative 
disadvantage to oral olanzapine. Last, level of functioning 
was assessed only at five points of time over the 2-year study. 
This prevented the ability to describe the detailed course of 
change in level of functioning over time.19
Conclusion
In this 2-year open-label, randomized study of patients with 
schizophrenia treated with olanzapine-LAI, most patients 
either maintained their favorable baseline level of function-
ing or further improved it over time. Although results did 
not differ significantly between the olanzapine-LAI and the 
oral olanzapine treatment groups, the lack of differentiation 
may have been driven by the fact that most patients who 
enrolled in this study were adherent and mildly ill, and are 
not patients who are typically treated with depot antipsychot-
ics in usual care.
Table 5 Proportion of patients in the “good”, “moderate”, and “poor” functioning clusters at last observation, by baseline functional 
cluster and treatment group
Treatment/functioning cluster  
at baseline
Functioning cluster at endpoint Total, n
“Good” “Moderate” “Poor”
Olanzapine-LAI, n (%)
“good” 35 (76.1) 11 (23.9) 0 (0.0) 46
“Moderate” 26 (18.8) 93 (67.4) 19 (13.8) 138
“Poor” 5 (9.1) 20 (36.4) 30 (54.5) 55
Total, n (%) 66 (27.6) 124 (51.9) 49 (20.5) 239
Oral olanzapine, n (%)
“good” 25 (73.5) 8 (23.5) 1 (2.9) 34
“Moderate” 30 (19.6) 110 (71.9) 13 (8.5) 153
“Poor” 1 (2.4) 18 (42.9) 23 (54.8) 42
Total, n (%) 56 (24.5) 136 (59.4) 37 (16.2) 229
Notes: There were no statistical differences between the change from baseline to endpoint for each of the functioning clusters when comparing olanzapine-lai and oral 
olanzapine. Percentages may not =100, due to rounding.
Abbreviation: lai, long-acting injection.
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